Literature DB >> 26817848

Body mass index in acute heart failure: association with clinical profile, therapeutic management and in-hospital outcome.

John Parissis1, Dimitrios Farmakis1, Nikolaos Kadoglou1, Ignatios Ikonomidis1, Ekaterini Fountoulaki1, Erifili Hatziagelaki1, Spyridon Deftereos1, Ferenc Follath2, Alexandre Mebazaa3, John Lekakis1, Gerasimos Filippatos1.   

Abstract

BACKGROUND: Increased body mass index (BMI) is a risk factor for heart failure, but evidence regarding BMI in acute heart failure (AHF) remains inconclusive. We sought to compare the clinical profile, treatment and in-hospital outcome across BMI categories in a large international AHF cohort.
METHODS: The Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF) is a retrospective survey on 4953 patients admitted for AHF from nine countries in Europe, Latin America, and Australia. Patients with unavailable BMI data or BMI <18.5 kg/m(2) were excluded. Clinical data and in-hospital mortality were compared among the following BMI categories: 18.5-24.9 kg/m(2) (normal weight), 25-29.9 kg/m(2) (overweight) and ≥30 kg/m(2) (obese).
RESULTS: Overweight/obese patients represented 75.7% of patients and had worse New York Heart Association class (P < 0.001) and higher admission systolic blood pressure (P < 0.001). The prevalence of comorbidities increased in parallel with BMI and included arterial hypertension, diabetes mellitus, dyslipidaemia (all P < 0.001), chronic obstructive pulmonary disease (P = 0.041) and chronic kidney disease (P = 0.056). Use of guideline-recommended medications also increased in parallel with BMI (angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, P < 0.001; β-blockers P < 0.001; mineralocorticoid receptors antagonist, P = 0.002). In-hospital mortality had a U-shaped relationship with BMI, with overweight patients having significantly lower rate (log-rank P = 0.027); this relationship vanished after adjustment for confounders.
CONCLUSIONS: Overweight/obese patients represented the vast majority of AHF cases, had a higher prevalence of non-cardiovascular comorbidities and were more likely to receive guideline-recommended medications. The U-shaped relationship between in-hospital mortality and BMI may be explained by differences in clinical profile and treatment and not by an effect of body composition per se.
© 2016 The Authors European Journal of Heart Failure © 2016 European Society of Cardiology.

Entities:  

Keywords:  Body mass index; Guideline-recommended therapies; Heart failure; Hospitalization; Mortality; Prognosis

Mesh:

Year:  2016        PMID: 26817848     DOI: 10.1002/ejhf.489

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  4 in total

1.  Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.

Authors:  Dimitrios Farmakis; Panagiotis Simitsis; Vasiliki Bistola; Filippos Triposkiadis; Ignatios Ikonomidis; Spyridon Katsanos; George Bakosis; Erifili Hatziagelaki; John Lekakis; Alexandre Mebazaa; John Parissis
Journal:  Clin Res Cardiol       Date:  2016-12-20       Impact factor: 5.460

2.  The Relationship Between Body Mass Index and In-hospital Survival in Patients Admitted With Acute Heart Failure.

Authors:  Gabby Elbaz-Greener; Guy Rozen; Shemy Carasso; Merav Yarkoni; Harindra C Wijeysundera; Ronny Alcalai; Israel Gotsman; Eldad Rahamim; David Planer; Offer Amir
Journal:  Front Cardiovasc Med       Date:  2022-04-28

3.  Effect of body mass index on clinical outcome and all-cause mortality in patients undergoing transcatheter aortic valve implantation.

Authors:  M Abawi; R Rozemeijer; P Agostoni; R C van Jaarsveld; C S van Dongen; M Voskuil; A O Kraaijeveld; P A F M Doevendans; P R Stella
Journal:  Neth Heart J       Date:  2017-09       Impact factor: 2.380

4.  Is There a Sex-Related Difference in the Obesity Paradox in Systolic Heart Failure? Sex-Related Difference in the Obesity Paradox.

Authors:  Soonchang Hong; Ji Hyun Lee; Kyung Min Kim; Jun Won Lee; Young Jin Youn; Min Soo Ahn; Sung Gyun Ahn; Seung Hwan Lee; Junghan Yoon; Kyung Hoon Choe; Byung Su Yoo
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.